Strata Skin Sciences, listed on NASDAQ as SSKN, is a global leader in advanced laser and light-based devices for serious skin disorders.
The company's existing business is operationally cash flow positive, with cash from operations reaching $0.2M in 2024.
Strata Skin Sciences anticipates a significant total addressable market (TAM) increase with a historic CPT code expansion unlocking over 30 million potential patients in January 2027.
Historic CPT Code Expansion
The upcoming CPT code expansion is expected to unlock over 30 million potential patients for Strata Skin Sciences, leading to a substantial increase in the total addressable market.
Increased Reimbursement per Patient
Submitting economic data to support an increase in reimbursement per treatment could significantly enhance Strata's TAM expansion strategy.
LaserOptek Lawsuit Impact
The lawsuit against LaserOptek, resulting in an injunction and potential damages, may bolster Strata Skin Sciences' cash position and market position.
- The introduction of new indications for use, including for inflammatory and autoimmune skin disorders, is set to broaden Strata's market reach significantly.
- The increased reimbursement per patient strategy aims to not only grow revenue per treatment but also attract more healthcare providers to partner with Strata for its advanced devices.
With a strong focus on expanding market potential, enhancing reimbursement rates, and leveraging legal victories, Strata Skin Sciences is poised for growth and innovation in the therapeutic and aesthetic dermatology sector.